Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1641 1642 1643 1645 1646 1798
This examiner grants 47% of resolved cases
Gary B Nickol is an examiner in Tech Center 1700 and Art Unit 1641. The examiner has 70 resolved cases. The data shows an allowance rate of 48.6 percent, which indicates the frequency of patent grants for applications in this unit. The median days to allowance for these cases is 1373. This timeframe provides a clear expectation for the duration of the prosecution process.
The interview lift is 28.9 percent. This figure suggests that conducting an interview has a significant impact on the probability of success compared to the 48.6 percent allowance rate. Applicants may find that verbal communication is a highly effective strategy. The 70 resolved cases provide a basis for these observations.
In Art Unit 1641, the 1373 median days to allowance reflects the typical speed of the examination cycle. The 28.9 percent interview lift represents a substantial improvement in outcomes. Practitioners should prioritize an interview when developing their strategy for Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18288696 | SELF-ACTIVATING FÖRSTER RESONANCE ENERGY TRANSFER (saFRET) BIOSENSORS AND METHODS FOR MAKING AND USING THEM | Non-Final OA | The Regents of the University of California |
| 18552141 | SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION | Final Rejection | The Regents of the University of California |
| 17251287 | SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | Final Rejection | The Regents of the University of California |
| 18297099 | COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34 | Non-Final OA | Eli Lilly and Company |
| 18261483 | MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME | Final Rejection | Washington University |
| 18531168 | TARGETING ANTI-HUMAN PD 1H/VISTA TO TREAT HEMATOLOGIC DISORDERS | Final Rejection | VANDERBILT UNIVERSITY |
| 18580889 | GENETICALLY ENGINEERED MULTIFUNCTIONAL EXOSOMES FOR IMMUNOTHERAPY | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 17995225 | TOCILIZUMAB FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | The University of Chicago |
| 18275616 | ANTI-IL1RAP ANTIBODIES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18533714 | BISPECIFIC ANTI-CCL2 ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18279938 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Final Rejection | University of Maryland, College Park |
| 18273796 | BLUE-GREEN ALGAE-CONTAINING TABLET | Non-Final OA | DIC Corporation |
| 18550739 | CD160 Binding Domain | Non-Final OA | UCL BUSINESS LTD |
| 18553703 | METHODS FOR DETERMINING TUMOR IMMUNE STATUS | Non-Final OA | Duke University |
| 18701187 | MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2 | Non-Final OA | The Hospital for Sick Children |
| 18274624 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | Non-Final OA | UNIVERSITÄT ULM |
| 18257804 | MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER | Final Rejection | MERUS N.V. |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | Final Rejection | MERUS N.V. |
| 18270139 | FORMULATION CONTAINING SOLUBLE GP130 DIMER AND METHOD FOR USING SAME | Non-Final OA | I-MAB BIOPHARMA (HANGZHOU) CO., LTD. |
| 17778382 | ANTI-PD-L1/ANTI-B7-H3 MULTISPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | I-MAB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy